Thank you for for making our 5th annual TVM Capital Life Science Autumn Conference 2016 which took place on Monday, September 19th in Montreal, a great success!
Our annual invitation only conference was attended by approx. 200 international participants from Asia, the United States and Europe who join us to network with senior decision makers from biotech and pharmaceutical companies as well as Venture Capital and investor groups.
We were very honored to welcome Dominique Anglade, Minister of Economy, Science and Innovation who was introduced by Vanessa Grant, Norton Rose Fulbright and Mr. Darren J. Carroll, Senior Vice President Corporate Business Development, Eli Lilly and Company, as the Keynote Speaker of this year’s event. We would like to thank our sponsors and supporters for their trust and continued support and look forward to seeing our international peers again next year!
Agenda |
|
| 11.30pm | Registration and light lunch |
| 12.30pm | Special Speaker: Dominique Anglade, Minister of Economy, Science and Innovation Introduction by Vanessa Grant, Norton Rose Fulbright |
| 12.45pm | Welcome Address Luc Marengere, Managing Partner, TVM Capital Life Science |
| 13.00pm | Keynote Speaker: Darren Carroll, Sr. Vice President, Corporate Business Development, Eli Lilly & Co Moderator and introduction: Hubert Birner, Managing Partner, TVM Capital Life Science |
| 1.45pm | Panel #1: Immune Oncology – Opportunities and Challenges: Wilson H. Miller, Jr., James McGill Professor in the Departments of Oncology and Medicine at McGill University Mario Sznol, Professor of Internal Medicine at Yale University School of Medicine, Greg Plowman, Vice President, Lilly Oncology Research / Senior Vice President, Imclone Systems Research Brian Stuglik, Founder, Proventus Health Solutions LLC Moderator and introduction: Marc Rivière, General Partner, TVM Capital Life Science |
| 2.45pm | Gary Muirhead, CEO of Ixchelsis Ltd. Moderator and introduction: Luc Marengere, Managing Partner, TVM Capital Life Science |
| 3.45pm | Coffee Break |
| 4.15pm | Panel #2: Orphan Drugs & Rare Diseases - Outlook for 2020 Chris Schelling, Founder and CEO of Acer Therapeutics Inc. André Turenne, Senior Vice President and Global Head of Business Development & Licensing at Sanofi Marlene Haffner, Haffner Associates, LLC, Orphan Solutions Alexandre Lebeaut, SVP and Head of Global Drug Development at Ipsen Moderator: Cynthia Lavoie, General Partner, TVM Capital Life Science |
| 5.15pm | Thomas P. Mathers, CEO of CoLucid Pharmaceuticals, Inc. Moderator and introduction: Marc Rivière, General Partner, TVM Capital Life Science |
| 6.00pm | Wrap up and Outlook Hubert Birner, Managing Partner, TVM Capital Life Science |
| 6.30pm | Evening Reception at Hotel Omni Mont-Royal, Room “Printemps” |
